Trial reportPharmacogenetics and genomics2013
Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.
Trial report in Pharmacogenetics and genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A systematic review of genome-wide association studies of antipsychotic response.Pharmacogenomics · 2019Pooled it
- Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth.Clinical pharmacology and therapeutics · 2026Article
- Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study.Frontiers in pharmacology · 2024Article
- Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Practice Effects, Test-Retest Reliability, and Minimal Detectable Change of the Ruff 2 and 7 Selective Attention Test in Patients with Schizophrenia.International journal of environmental research and public health · 2021Article
- Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia.BJPsych open · 2021Article
- Variants in regulatory elements of PDE4D associate with major mental illness in the Finnish population.Molecular psychiatry · 2021Article
- The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.Complex psychiatry · 2020Review
- Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.Molecular neuropsychiatry · 2020Review
- Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.Human genomics · 2020Article
- Pharmacogenomic Characterization in Bipolar Spectrum Disorders.Pharmaceutics · 2019Review
- Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.Current psychiatry reports · 2018Review
- [Pharmacogenetics in psychiatry: state of the art].Der Nervenarzt · 2018Review
- Genome-wide association study of paliperidone efficacy.Pharmacogenetics and genomics · 2017Article
- Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.Omics : a journal of integrative biology · 2016Review
- Gray matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy: An exploratory study.Medicine · 2016Article
- Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.The pharmacogenomics journal · 2016Article
- Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.Public health genomics · 2015Review
- Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.Discovery medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
objectiveTo examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia. MATERIALS AND
methodsWe performed GWAS to search for genetic variation affecting treatment response. The analysis sample included 738 patients with schizophrenia, successfully genotyped for ∼492k single nucleotide polymorphisms (SNPs) from the Clinical Antipsychotic Trial of Intervention Effectiveness. Outcomes included both clinician and patient report of illness severity on global impression scales, the clinical global impression severity scale and patient global impression, respectively. Our criterion for genome-wide significance was a prespecified threshold ensuring that, on average, only 10% of the significant findings are false discoveries.
resultsThirteen SNPs reached genome-wide significance. The top findings indicated three SNPs in PDE4D, 5q12.1 (P=4.2×10, 1.6×10, 1.8×10), mediating the effects of quetiapine on patient-reported severity and an additional three SNPs in TJP1, 15q13.1 (P=2.25×10, 4.86×10, 4.91×10), mediating the effects of risperidone on patient-reported severity. For clinician-reported severity, two SNPs in PPA2, 4q24 (P=3.68×10, 5.05×10), were found to reach genome-wide significance.
conclusionWe found evidence of both a novel and a consistent association when examining the results from the patient and clinician ratings, suggesting that different raters may capture unique facets of schizophrenia. Although our findings require replication and functional validation, this study shows the potential of GWAS to discover genes that potentially mediate treatment response of antipsychotic medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.